Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

Eli Lilly and Company has announced new data from the Phase 1 AJX-101 study, showcasing the investigational type II JAK2 inhibitor's efficacy and safety in patients with previously treated myelofibrosis. This breakthrough marks a significant step forward in the pursuit of a novel treatment strategy for this debilitating blood disorder. The AJX-101 study has demonstrated promising results, with the investigational compound demonstrating a favorable safety profile and encouraging clinical activity in patients with previously treated myelofibrosis. The presentation of these findings at the 2026 EHA Annual Meeting will provide a platform for the scientific community to engage with the data and further understand the potential of this investigational treatment. The presentation of initial clinical data for a first-in-class type II JAK2 inhibitor marks a crucial milestone in the development of a potential new treatment option for patients with previously treated myelofibrosis.